- Home
- ITOS
as 11-22-2024 4:00pm EST
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 342.6M | IPO Year: | 2020 |
| Target Price: | $33.67 | AVG Volume (30 days): | 543.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.54 - $18.75 | Next Earning Date: | 11-12-2024 |
| Revenue: | $35,000,000 | Revenue Growth: | -47.37% |
| Revenue Growth (this year): | 271.18% | Revenue Growth (next year): | -85.39% |
Latest iTeos Therapeutics Inc. News
ITOS Breaking Stock News: Dive into ITOS Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
GlobeNewswire
11 days ago
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
a month ago
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
GuruFocus.com
a month ago
BOXER CAPITAL, LLC Expands Stake in ITeos Therapeutics Inc
GuruFocus.com
2 months ago
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics Inc
Investor's Business Daily
2 months ago
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
MT Newswires
2 months ago
Wedbush Raises Price Target on iTeos Therapeutics to $25 From $21, Keeps Outperform Rating
Pharmaceutical Technology
2 months ago
ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC
Compare ITOS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITOS iTeos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.